1. Home
  2. CRNX
  3. CRNX News

Latest Crinetics Pharmaceuticals Inc. (CRNX) News on November 17, 2024

Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences
CRNX

GlobeNewswire

2 days ago

Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences

UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting
CRNX

GlobeNewswire

3 days ago

UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting

Crinetics Pharmaceuticals Third Quarter 2024 Earnings: US$0.96 loss per share (vs US$1.01 loss in 3Q 2023)
CRNX

Simply Wall St.

3 days ago

Crinetics Pharmaceuticals Third Quarter 2024 Earnings: US$0.96 loss per share (vs US$1.01 loss in 3Q 2023)

Crinetics Pharmaceuticals Inc (CRNX) Q3 2024 Earnings Call Highlights: Strategic Advances and ...
CRNX

GuruFocus.com

4 days ago

Crinetics Pharmaceuticals Inc (CRNX) Q3 2024 Earnings Call Highlights: Strategic Advances and ...

CRNX

MT Newswires

5 days ago

Crinetics Pharmaceuticals Q3 Net Loss Narrows

Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting
CRNX

GlobeNewswire

5 days ago

Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting

Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
CRNX

GlobeNewswire

5 days ago

Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Crinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CRNX

GlobeNewswire

6 days ago

Crinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Investors might be losing patience for Crinetics Pharmaceuticals' (NASDAQ:CRNX) increasing losses, as stock sheds 5.6% over the past week
CRNX

Simply Wall St.

18 days ago

Investors might be losing patience for Crinetics Pharmaceuticals' (NASDAQ:CRNX) increasing losses, as stock sheds 5.6% over the past week

State Street Corp's Strategic Acquisition in Crinetics Pharmaceuticals
CRNX

GuruFocus.com

a month ago

State Street Corp's Strategic Acquisition in Crinetics Pharmaceuticals

Crinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024
CRNX

GlobeNewswire

a month ago

Crinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024

Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CRNX

GlobeNewswire

a month ago

Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Morning Movers: Arcadium Lithium surges after deal to be acquired
CRNX

TipRanks

a month ago

Morning Movers: Arcadium Lithium surges after deal to be acquired

Crinetics Pharmaceuticals Inc (CRNX) Q2 2024 Earnings Call Highlights: Strategic Advances Amid ...
CRNX

GuruFocus.com

a month ago

Crinetics Pharmaceuticals Inc (CRNX) Q2 2024 Earnings Call Highlights: Strategic Advances Amid ...

CRNX

MT Newswires

a month ago

Update: Crinetics Pharmaceuticals Prices $500 Million Stock Offering

CRNX

MT Newswires

a month ago

Crinetics Pharmaceuticals Prices $500 Million Stock Offering

Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
CRNX

GlobeNewswire

a month ago

Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

CRNX

MT Newswires

a month ago

Crinetics Pharmaceuticals Plans $400 Million Stock Sale

Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
CRNX

GlobeNewswire

a month ago

Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock

CRNX

MT Newswires

a month ago

Crinetics Pharmaceuticals Insider Sold Shares Worth $785,306, According to a Recent SEC Filing

CRNX

MT Newswires

2 months ago

Crinetics Pharmaceuticals Files New Drug Application for Acromegaly Treatment

Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly
CRNX

GlobeNewswire

2 months ago

Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly

Insider Sale: Chief Scientific Officer Stephen Betz Sells Shares of Crinetics Pharmaceuticals ...
CRNX

GuruFocus.com

2 months ago

Insider Sale: Chief Scientific Officer Stephen Betz Sells Shares of Crinetics Pharmaceuticals ...

Crinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CRNX

GlobeNewswire

2 months ago

Crinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals, Inc. (CRNX): Among the Best Mid-Cap Healthcare Stocks To Buy Now
CRNX

Insider Monkey

2 months ago

Crinetics Pharmaceuticals, Inc. (CRNX): Among the Best Mid-Cap Healthcare Stocks To Buy Now

Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences
CRNX

GlobeNewswire

3 months ago

Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences

Insider Sale: Chief Scientific Officer Stephen Betz Sells 3,000 Shares of Crinetics ...
CRNX

GuruFocus.com

3 months ago

Insider Sale: Chief Scientific Officer Stephen Betz Sells 3,000 Shares of Crinetics ...

Insider Sale: Chief Scientific Officer Stephen Betz Sells 3,000 Shares of Crinetics ...
CRNX

GuruFocus.com

3 months ago

Insider Sale: Chief Scientific Officer Stephen Betz Sells 3,000 Shares of Crinetics ...

Crinetics Pharmaceuticals Announces August 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CRNX

GlobeNewswire

3 months ago

Crinetics Pharmaceuticals Announces August 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

We Think Crinetics Pharmaceuticals (NASDAQ:CRNX) Can Afford To Drive Business Growth
CRNX

Simply Wall St.

3 months ago

We Think Crinetics Pharmaceuticals (NASDAQ:CRNX) Can Afford To Drive Business Growth

CRNX

MT Newswires

3 months ago

Oppenheimer Trims Crinetics Pharmaceuticals Price Target to $73 From $74, Maintains Outperform Rating

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Misses Revenue Estimates
CRNX

Zacks

3 months ago

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Misses Revenue Estimates

Crinetics Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
CRNX

GlobeNewswire

3 months ago

Crinetics Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Crinetics Launches ACRO/TRUTH Educational Initiative to Raise Awareness of Acromegaly Treatment Challenges
CRNX

GlobeNewswire

3 months ago

Crinetics Launches ACRO/TRUTH Educational Initiative to Raise Awareness of Acromegaly Treatment Challenges

Earnings Preview: Zevra Therapeutics (ZVRA) Q2 Earnings Expected to Decline
CRNX

Zacks

3 months ago

Earnings Preview: Zevra Therapeutics (ZVRA) Q2 Earnings Expected to Decline

Crinetics Pharmaceuticals, Inc. (CRNX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
CRNX

Zacks

4 months ago

Crinetics Pharmaceuticals, Inc. (CRNX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Insider Sale: Chief Scientific Officer Stephen Betz Sells Shares of Crinetics Pharmaceuticals ...
CRNX

GuruFocus.com

4 months ago

Insider Sale: Chief Scientific Officer Stephen Betz Sells Shares of Crinetics Pharmaceuticals ...

Crinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024
CRNX

GlobeNewswire

4 months ago

Crinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024

CRNX

MT Newswires

4 months ago

Crinetics Pharmaceuticals Insider Sold Shares Worth $1,485,000, According to a Recent SEC Filing

Insider Sale: Chief Scientific Officer Stephen Betz Sells Shares of Crinetics Pharmaceuticals ...
CRNX

GuruFocus.com

4 months ago

Insider Sale: Chief Scientific Officer Stephen Betz Sells Shares of Crinetics Pharmaceuticals ...

Crinetics Pharmaceuticals Announces July 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CRNX

GlobeNewswire

4 months ago

Crinetics Pharmaceuticals Announces July 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CRNX

MT Newswires

4 months ago

JPMorgan Raises Price Target on Crinetics Pharmaceuticals to $54 From $47, Maintains Overweight Rating

Insider Sale: Chief Scientific Officer Stephen Betz Sells Shares of Crinetics Pharmaceuticals ...
CRNX

GuruFocus.com

5 months ago

Insider Sale: Chief Scientific Officer Stephen Betz Sells Shares of Crinetics Pharmaceuticals ...

CRNX

MT Newswires

5 months ago

Crinetics Pharmaceuticals Insider Sold Shares Worth $434,435, According to a Recent SEC Filing

EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner
CRNX

GlobeNewswire

5 months ago

EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner

Insider Sale at Crinetics Pharmaceuticals Inc (CRNX): Chief Scientific Officer Stephen Betz ...
CRNX

GuruFocus.com

5 months ago

Insider Sale at Crinetics Pharmaceuticals Inc (CRNX): Chief Scientific Officer Stephen Betz ...

Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CRNX

GlobeNewswire

5 months ago

Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition
CRNX

Business Wire

5 months ago

Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition

Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus
CRNX

GlobeNewswire

5 months ago

Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus

Share buy-back programme - week 23
CRNX

GlobeNewswire

5 months ago

Share buy-back programme - week 23

Do Scientex Berhad's (KLSE:SCIENTX) Earnings Warrant Your Attention?
CRNX

Simply Wall St.

5 months ago

Do Scientex Berhad's (KLSE:SCIENTX) Earnings Warrant Your Attention?

Japan's service sector mood hits nearly 2-year low in May
CRNX

Reuters

5 months ago

Japan's service sector mood hits nearly 2-year low in May

N. Korea sends more balloons as Kim's sister warns of 'new counteraction'
CRNX

AFP

5 months ago

N. Korea sends more balloons as Kim's sister warns of 'new counteraction'

Enduring role of 'treasuring the past' hailed
CRNX

PR Newswire

5 months ago

Enduring role of 'treasuring the past' hailed

Velcan Holdings: buyback offer of 500 000 shares at Eur 14.5 per share
CRNX

GlobeNewswire

5 months ago

Velcan Holdings: buyback offer of 500 000 shares at Eur 14.5 per share

CRNX

MT Newswires

5 months ago

Oppenheimer Raises Price Target on Crinetics Pharmaceuticals to $74 From $55, Maintains Outperform Rating

Crinetics Unveils 'Stunning' Results In Highly Anticipated Study
CRNX

Investor's Business Daily

5 months ago

Crinetics Unveils 'Stunning' Results In Highly Anticipated Study

Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing’s Syndrome (ADCS)
CRNX

GlobeNewswire

5 months ago

Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing’s Syndrome (ADCS)

Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly
CRNX

GlobeNewswire

5 months ago

Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly

Shareholders Will Probably Not Have Any Issues With Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) CEO Compensation
CRNX

Simply Wall St.

6 months ago

Shareholders Will Probably Not Have Any Issues With Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) CEO Compensation

Insider Sale: Chief Scientific Officer Stephen Betz Sells 3,000 Shares of Crinetics ...
CRNX

GuruFocus.com

6 months ago

Insider Sale: Chief Scientific Officer Stephen Betz Sells 3,000 Shares of Crinetics ...

Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affairs
CRNX

GlobeNewswire

6 months ago

Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affairs

CRNX

MT Newswires

6 months ago

Morgan Stanley Raises Price Target on Crinetics Pharmaceuticals to $70 From $50, Maintains Overweight Rating

Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts
CRNX

GlobeNewswire

6 months ago

Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q1 2024 Earnings Call Transcript
CRNX

Insider Monkey

6 months ago

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q1 2024 Earnings Call Transcript

Investors in Crinetics Pharmaceuticals (NASDAQ:CRNX) have seen solid returns of 196% over the past three years
CRNX

Simply Wall St.

6 months ago

Investors in Crinetics Pharmaceuticals (NASDAQ:CRNX) have seen solid returns of 196% over the past three years

Crinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CRNX

GlobeNewswire

6 months ago

Crinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CRNX

MT Newswires

6 months ago

Crinetics Pharmaceuticals Insider Sold Shares Worth $5,307,931, According to a Recent SEC Filing

Crinetics Pharmaceuticals Inc (CRNX) Reports Q1 2024 Financial Results
CRNX

GuruFocus.com

6 months ago

Crinetics Pharmaceuticals Inc (CRNX) Reports Q1 2024 Financial Results

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Misses Revenue Estimates
CRNX

Zacks

6 months ago

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Misses Revenue Estimates

CRNX

MT Newswires

6 months ago

Crinetics Pharmaceuticals Q1 Net Loss Widens

Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
CRNX

GlobeNewswire

6 months ago

Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024
CRNX

GlobeNewswire

6 months ago

Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024

CRNX

MT Newswires

6 months ago

Piper Sandler Adjusts Price Target on Crinetics Pharmaceuticals to $97 From $56, Maintains Overweight Rating

Crinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024
CRNX

GlobeNewswire

6 months ago

Crinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024

Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CRNX

GlobeNewswire

7 months ago

Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Insider Sell: COO Jeff Knight Sells 32,359 Shares of Crinetics Pharmaceuticals Inc (CRNX)
CRNX

GuruFocus.com

8 months ago

Insider Sell: COO Jeff Knight Sells 32,359 Shares of Crinetics Pharmaceuticals Inc (CRNX)

Insider Sell: Chief Medical and Development Officer Dana Pizzuti Sells 15,089 Shares of ...
CRNX

GuruFocus.com

8 months ago

Insider Sell: Chief Medical and Development Officer Dana Pizzuti Sells 15,089 Shares of ...

Director Matthew Fust Sells 60,000 Shares of Crinetics Pharmaceuticals Inc (CRNX)
CRNX

GuruFocus.com

8 months ago

Director Matthew Fust Sells 60,000 Shares of Crinetics Pharmaceuticals Inc (CRNX)

Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More
CRNX

Zacks

8 months ago

Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More

Crinetics Pharmaceuticals Inc CFO Marc Wilson Sells 6,942 Shares
CRNX

GuruFocus.com

8 months ago

Crinetics Pharmaceuticals Inc CFO Marc Wilson Sells 6,942 Shares

Crinetics Pharmaceuticals (CRNX) Stock Jumps 19.1%: Will It Continue to Soar?
CRNX

Zacks

8 months ago

Crinetics Pharmaceuticals (CRNX) Stock Jumps 19.1%: Will It Continue to Soar?

Endocrine Disease-Focused Crinetics Pharmaceuticals Stock Soars On Tuesday - Here's Why
CRNX

Benzinga

8 months ago

Endocrine Disease-Focused Crinetics Pharmaceuticals Stock Soars On Tuesday - Here's Why

Crinetics Stock Jets 19% Higher, Reversing A Three-Week Decline On Its Phase 3 Win
CRNX

Investor's Business Daily

8 months ago

Crinetics Stock Jets 19% Higher, Reversing A Three-Week Decline On Its Phase 3 Win

Biotech Stock Crinetics Jets Higher On Second Phase 3 Trial Win
CRNX

Investor's Business Daily

8 months ago

Biotech Stock Crinetics Jets Higher On Second Phase 3 Trial Win

CRNX

Reuters

8 months ago

UPDATE 2-Crinetics' hormonal disorder drug succeeds in late-stage study

CRNX

Reuters

8 months ago

Crinetics Pharma's hormonal disorder drug meets main goal in late-stage study

Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
CRNX

GlobeNewswire

8 months ago

Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients

Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
CRNX

GlobeNewswire

8 months ago

Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome

Crinetics Pharmaceuticals Announces March 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CRNX

GlobeNewswire

8 months ago

Crinetics Pharmaceuticals Announces March 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q4 2023 Earnings Call Transcript
CRNX

Insider Monkey

9 months ago

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q4 2023 Earnings Call Transcript

Crinetics Pharmaceuticals Full Year 2023 Earnings: Misses Expectations
CRNX

Simply Wall St.

9 months ago

Crinetics Pharmaceuticals Full Year 2023 Earnings: Misses Expectations

CRNX

GuruFocus.com

9 months ago

Crinetics Pharmaceuticals Inc (CRNX) Reports Increased R&D Investment Amidst Net Loss ...

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
CRNX

GlobeNewswire

9 months ago

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
CRNX

GlobeNewswire

9 months ago

Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement

Steven Cohen Adjusts Position in Crinetics Pharmaceuticals Inc
CRNX

GuruFocus.com

9 months ago

Steven Cohen Adjusts Position in Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
CRNX

GlobeNewswire

9 months ago

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024

Crinetics Pharmaceuticals Announces February 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CRNX

GlobeNewswire

9 months ago

Crinetics Pharmaceuticals Announces February 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Modine Manufacturing Co (MOD) Reports Solid Q3 Fiscal 2024 Results and Raises Full-Year Guidance
CRNX

GuruFocus.com

10 months ago

Modine Manufacturing Co (MOD) Reports Solid Q3 Fiscal 2024 Results and Raises Full-Year Guidance

ManpowerGroup Inc (MAN) Faces Headwinds: Q4 Earnings Reveal Challenges and Resilience
CRNX

GuruFocus.com

10 months ago

ManpowerGroup Inc (MAN) Faces Headwinds: Q4 Earnings Reveal Challenges and Resilience

Share on Social Networks: